Last reviewed · How we verify
NCT05657418
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
Phase 1 trial testing JS107 in Advanced Pancreatic Cancer in 8 participants. Terminated before completion.
4 January 2025
Quick facts
| Lead sponsor | Shanghai Junshi Bioscience Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 29 March 2022 |
| Primary completion | 4 January 2025 |
| Estimated completion | 4 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- JS107 — full drug profile →
- JS107 combination with Toripalimab
Conditions studied
- Advanced Pancreatic Cancer — all drugs for Advanced Pancreatic Cancer →
Sponsor
Shanghai Junshi Bioscience Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05657418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JS107
Trials testing the same drug.
- NCT05502393 — A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors · Phase 1 · unknown
Other recruiting trials for Advanced Pancreatic Cancer
Currently open trials in the same condition.
- NCT07416240 — Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. · EARLY_PHASE1 · recruiting
- NCT07006077 — Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT06111274 — A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT06078787 — Olaparib in PALB2 Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT05916261 — Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer · EARLY_PHASE1 · recruiting
Other Shanghai Junshi Bioscience Co., Ltd. trials
Trials by the same sponsor.
- NCT07503756 — JS212 Combination Therapies in Metastatic Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
- NCT07484724 — A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Ce · Phase 2 · not yet recruiting
- NCT07518160 — JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study · Phase 2 · not yet recruiting
- NCT07309276 — A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05657418 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Junshi Bioscience Co., Ltd.
- Last refreshed: 6 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05657418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing